Outlook Therapeutics, Inc. (NASDAQ:OTLK)
| Market Cap | 124.84M-38.8% |
| Revenue (ttm) | -1.16M-177.3% |
| Net Income | -61.12M-40.7% |
| EPS | -0.33-83.3% |
| Shares Out | 187.00M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,091,207 |
| Open | 0.67 |
| Previous Close | 0.66 |
| Day's Range | 0.66 - 0.68 |
| 52-Week Range | 0.16 - 2.54 |
| Beta | 0.75 |
| Analysts | Buy |
| Price Target | 2.80(+319.41%) |
| Earnings Date | Dec 18, 2026 |
About OTLK
Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced stages of clinical development, focused on inventing and bringing to market monoclonal antibody treatments for various eye conditions. Its flagship drug candidate, ONS-5010, is an ophthalmic formulation of bevacizumab currently undergoing crucial Phase III clinical trials. This investigational product is being evaluated for its potential to treat wet age-related macular degeneration and other serious retinal diseases. The company has forged strategic collaboration and licensing agreements with several partners, including IPCA Laboratories Limited, Laboratorios Liomont, S.A. de C.V., BioLexis Pte. Ltd., and Zhejiang Huahai Pharmaceutical Co., Ltd. Incorporated in 2010, the firm was formerly known as Oncobiologics, Inc., changing its name to Outlook Therapeutics, Inc. in November 2018. Its corporate base is located in Iselin, New Jersey.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$OTLK stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in OTLK holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by OTLK's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
OTLK Estimated quarterly lobbying spending
Source: U.S. Senate LDA
OTLK Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| ONS-5010/LYTENAVA development | $2.19M | 43.08% |
| Professional fees | $1.17M | 23.12% |
| Facilities, fees and other related costs | $1.09M | 21.38% |
| Compensation and related benefits | $567.19K | 11.17% |
| Stock-based compensation | $63.27K | 1.25% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New OTLK patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to OTLK from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in OTLK
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $3.00M |
| VXFVanguard Extended Market ETF | $1.20M |
Estimated from each fund’s disclosed top holdings × AUM
OTLK Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from OTLK’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score